洞察市场格局
解锁药品研发情报

400客服电话

  • 购买数据产品

    400-9696-311 转1

  • 定制咨询业务

    400-9696-311 转2

  • 数据与AI定制业务

    400-9696-311 转3

  • 商务合作及其他问题

    400-9696-311 转4

  • 投诉及建议

    400-9696-311 转5

医药数据查询

【ChiCTR-IIN-17014220】Effects of Tai Chi on cognition and instrumental activities of daily living in community dwelling older people with mild cognitive impairment

基本信息
登记号

ChiCTR-IIN-17014220

试验状态

结束

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2017-12-30

临床申请受理号

/

靶点

/

适应症

Mild cognitive impairment

试验通俗题目

Effects of Tai Chi on cognition and instrumental activities of daily living in community dwelling older people with mild cognitive impairment

试验专业题目

Effects of Tai Chi on cognition and instrumental activities of daily living in community dwelling older people with mild cognitive impairment

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

联系人通讯地址
请登录查看
临床试验信息
试验目的

The objectives of the study are to determine the effect of Tai Chi on the following variables among community-dwelling older adults with MCI in Hong Kong: 1. cognitive functions in relation to general cognitive status; 2. functional capability in terms of instrumental ADL.

试验分类
请登录查看
试验类型

非随机对照试验

试验分期

Ⅰ期

随机化

This was a quasi-experimental study which adopted a multisite nonequivalent control group pre- and post-test design. No randomization had taken place.

盲法

Not applicable

试验项目经费来源

No funding applied

试验范围

/

目标入组人数

80

实际入组人数

/

第一例入组时间

2015-12-01

试验终止时间

2016-09-01

是否属于一致性

/

入选标准

The inclusion criteria for the study were: (1) Chinese people aged 60 years or above; (2) the CMMSE screening score ranging from 19 to 28, which was corrected based on educational level (≥ 18 for illiterate respondents and ≥ 22 for those having received more than two years of schooling). The CMMSE score of 19 was set as the bottom limit because previous studies have found that older adults with MMSE scores of 18 can provide valid answers to inquiries and are able to follow instructions. At the upper limit, some elderly persons with MMSE scores of 28 may exhibit symptoms of memory deficit; (3) ability to perform self-care functions on their own; (4) no confirmed diagnosis of dementia, depression or other psychiatric illnesses which would interfere with cognitive performance; and (5) no engagement in any structured physical exercise program or Tai Chi practice in the preceding year.;

排除标准

Elderly persons were excluded from the study if they: (1) had a medical history of chronic alcoholism or brain trauma occurred in previous years that could interfere with cognition; (2) had been regular users of medications that could affect cognition; or (3) had clinical conditions that contraindicated light to moderate physical exercise.;

研究者信息
研究负责人姓名
请登录查看
试验机构

Nil

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

/

联系人通讯地址
请登录查看
更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

Nil的其他临床试验

最新临床资讯

摩熵医药企业版
50亿+条医药数据随时查
7天免费试用

全球药物研发中心
全球研发数据与行业前沿情报

383,318
全球在研药物数
964
本月临床试验数
全球批准的新药
更多
全球首批
各国首批
数据来源:摩熵医药
更新时间:
研发动态
相关报告
政策法规
更多信息,请进入全球药物研发中心查看

医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测

2,630亿元
2026年Q2总销售额
6.14%(2026Q2)
TOP5企业市场份额
药品销售排行榜
查看完整数据
2025Q4医院化学药销售增速 *按市场份额排序
  • 1
    甲氨蝶呤注射液
  • 2
    克霉唑阴道乳膏
  • 3
    氯化钠注射液
核心能力
  • 医药市场销售数据分析 · 医院、实体药店、网上药店
  • 市场竞争格局分析(靶点、药品类型、ATC大类)
更多信息,请进入医药市场洞察中心查看